PURPOSE: To determine the role of amifostine as a protectant against cisplatin-induced ototoxicity in patients with average-risk (AR) medulloblastoma treated with craniospinal radiotherapy and four cycles of cisplatin-based, dose-intense chemotherapy and stem-cell rescue. PATIENTS AND METHODS: The primary objective was to determine whether, in patients with AR medulloblastoma (n = 62), amifostine would decrease the need for hearing aids (defined as >or= grade 3 ototoxicity in one ear) compared with a control group (n = 35), 1 year from initiating treatment. Ninety-seven patients received craniospinal irradiation (23.4 Gy) followed by 55.8 Gy to the primary tumor bed using three-dimensional conformal technique, and four cycles of high-dose cyclophosphamide (4,000 mg/m(2)/cycle), cisplatin (75 mg/m(2)/cycle), and vincristine (two 1.5 mg/m(2) doses/cycle) and stem-cell rescue. When used, amifostine (600 mg/m(2)/dose) was administered as a bolus immediately before and 3 hours into the cisplatin infusion. RESULTS: The median age of the 97 patients was 8.7 years (range, 3.2 to 20.2 years). The study and control groups were similar in age and sex distribution. Amifostine was well-tolerated. One year after treatment initiation, 13 patients (37.1%) in the control group versus nine (14.5%; one-sided chi(2) test P = .005) of the amifostine-treated patients had at least grade 3 ototoxicity, requiring hearing aid in at least one ear. CONCLUSION: Amifostine administered before and during the cisplatin infusion can significantly reduce the risk of severe ototoxicity in patients with AR medulloblastoma receiving dose-intense chemotherapy.
PURPOSE: To determine the role of amifostineas a protectant against cisplatin-induced ototoxicity in patients with average-risk (AR) medulloblastoma treated with craniospinal radiotherapy and four cycles of cisplatin-based, dose-intense chemotherapy and stem-cell rescue. PATIENTS AND METHODS: The primary objective was to determine whether, in patients with AR medulloblastoma (n = 62), amifostine would decrease the need for hearing aids (defined as >or= grade 3 ototoxicity in one ear) compared with a control group (n = 35), 1 year from initiating treatment. Ninety-seven patients received craniospinal irradiation (23.4 Gy) followed by 55.8 Gy to the primary tumor bed using three-dimensional conformal technique, and four cycles of high-dose cyclophosphamide (4,000 mg/m(2)/cycle), cisplatin (75 mg/m(2)/cycle), and vincristine (two 1.5 mg/m(2) doses/cycle) and stem-cell rescue. When used, amifostine (600 mg/m(2)/dose) was administered as a bolus immediately before and 3 hours into the cisplatin infusion. RESULTS: The median age of the 97 patients was 8.7 years (range, 3.2 to 20.2 years). The study and control groups were similar in age and sex distribution. Amifostine was well-tolerated. One year after treatment initiation, 13 patients (37.1%) in the control group versus nine (14.5%; one-sided chi(2) test P = .005) of the amifostine-treated patients had at least grade 3 ototoxicity, requiring hearing aid in at least one ear. CONCLUSION:Amifostine administered before and during the cisplatin infusion can significantly reduce the risk of severe ototoxicity in patients with AR medulloblastoma receiving dose-intense chemotherapy.
Authors: D Strother; D Ashley; S J Kellie; A Patel; D Jones-Wallace; S Thompson; R Heideman; E Benaim; R Krance; L Bowman; A Gajjar Journal: J Clin Oncol Date: 2001-05-15 Impact factor: 44.544
Authors: L L Muldoon; M A Pagel; R A Kroll; R E Brummett; N D Doolittle; E G Zuhowski; M J Egorin; E A Neuwelt Journal: Clin Cancer Res Date: 2000-01 Impact factor: 12.531
Authors: R J Packer; J Goldwein; H S Nicholson; L G Vezina; J C Allen; M D Ris; K Muraszko; L B Rorke; W M Wara; B H Cohen; J M Boyett Journal: J Clin Oncol Date: 1999-07 Impact factor: 44.544
Authors: Thomas E Merchant; Ciara J Gould; Xiaoping Xiong; Nicole Robbins; Junhong Zhu; David L Pritchard; Raja Khan; Richard L Heideman; Matthew J Krasin; Larry E Kun Journal: Int J Radiat Oncol Biol Phys Date: 2004-03-15 Impact factor: 7.038
Authors: Heng Xu; Giles W Robinson; Jie Huang; Joshua Yew-Suang Lim; Hui Zhang; Johnnie K Bass; Alberto Broniscer; Murali Chintagumpala; Ute Bartels; Sri Gururangan; Tim Hassall; Michael Fisher; Richard Cohn; Tetsuji Yamashita; Tal Teitz; Jian Zuo; Arzu Onar-Thomas; Amar Gajjar; Clinton F Stewart; Jun J Yang Journal: Nat Genet Date: 2015-02-09 Impact factor: 38.330
Authors: Daniel M Green; Larry E Kun; Katherine K Matthay; Anna T Meadows; William H Meyer; Paul A Meyers; Sheri L Spunt; Leslie L Robison; Melissa M Hudson Journal: Pediatr Blood Cancer Date: 2013-02-15 Impact factor: 3.167
Authors: Ibrahim Qaddoumi; Johnnie K Bass; Jianrong Wu; Catherine A Billups; Amy W Wozniak; Thomas E Merchant; Barrett G Haik; Matthew W Wilson; Carlos Rodriguez-Galindo Journal: J Clin Oncol Date: 2012-02-27 Impact factor: 44.544
Authors: Johnnie K Bass; Jie Huang; Arzu Onar-Thomas; Kay W Chang; Shaum P Bhagat; Murali Chintagumpala; Ute Bartels; Sridharan Gururangan; Tim Hassall; John A Heath; Geoffrey McCowage; Richard J Cohn; Michael J Fisher; Giles Robinson; Alberto Broniscer; Amar Gajjar; James G Gurney Journal: Pediatr Blood Cancer Date: 2013-11-01 Impact factor: 3.167
Authors: James G Gurney; Johnnie K Bass; Arzu Onar-Thomas; Jie Huang; Murali Chintagumpala; Eric Bouffet; Tim Hassall; Sridharan Gururangan; John A Heath; Stewart Kellie; Richard Cohn; Michael J Fisher; Atmaram Pai Panandiker; Thomas E Merchant; Ashok Srinivasan; Cynthia Wetmore; Ibrahim Qaddoumi; Clinton F Stewart; Gregory T Armstrong; Alberto Broniscer; Amar Gajjar Journal: Neuro Oncol Date: 2014-01-10 Impact factor: 12.300
Authors: Debashree Mukherjea; Sarvesh Jajoo; Tejbeer Kaur; Kelly E Sheehan; Vickram Ramkumar; Leonard P Rybak Journal: Antioxid Redox Signal Date: 2010-09-01 Impact factor: 8.401
Authors: Surya Rednam; Michael E Scheurer; Adekunle Adesina; Ching C Lau; Mehmet Fatih Okcu Journal: Pediatr Blood Cancer Date: 2012-10-12 Impact factor: 3.167